Walmart has reached a settlement regarding a lawsuit filed by the US government concerning alleged violations related to opioids
Walmart has reached a settlement regarding a lawsuit from the US government that accused the company of failing to properly manage and oversee opioid prescriptions.
Walmart has reached a settlement regarding a lawsuit from the US government, which claimed that its pharmacies did not comply with federal regulations related to the handling and dispensing of opioids and other controlled substances.
The US Justice Department announced that the settlement addresses claims that Walmart did not fulfill its responsibilities under the Controlled Substances Act regarding the monitoring and dispensing of controlled medications.
Information regarding the settlement, including any financial aspects, was not promptly revealed.
The Justice Department expressed satisfaction in resolving the allegations against Walmart and its pharmacies.
Walmart confirmed the agreement, expressing satisfaction in resolving the matter and reaffirming its commitment to support its pharmacists in delivering quality care to patients.
The Justice Department filed a lawsuit against Walmart in 2020, alleging that the retailer from Bentonville, Arkansas, has consistently breached the federal Controlled Substances Act since 2013.
Federal authorities indicated that Walmart might incur billions of dollars in civil penalties due to the alleged violations.
The settlement comes after Walmart’s commitment in 2022 to pay $3.1 billion to address numerous lawsuits filed by state and local governments regarding its purported involvement in the opioid crisis.
The opioid epidemic has resulted in hundreds of thousands of fatalities throughout the United States and continues to be a significant public health issue.
Opioid-related deaths have seen a decline recently, as reported by the US Centers for Disease Control and Prevention. However, the issues of opioid misuse and overdose continue to pose a substantial public health challenge.
